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unpredictable therapeutic outcomes impeding practice adoption. Means to establish and certify the regenerative potency of emerging
biotherapies are thus warranted. In this era of clinomics, deconvolution of variant cytoreparative performance in clinical trials offers an
unprecedented opportunity to map pathways that segregate regenerative from non-regenerative states informing the evolution of
cardio-regenerative quality systems. A maiden example of this approach is cardiopoiesis-mediated lineage speciﬁcation developed to
ensure regenerative performance. Successfully tested in pre-clinical and early clinical studies, the safety and efﬁcacy of the cardiopoietic
stem cell phenotype is undergoing validation in pivotal trials for chronic ischemic cardiomyopathy offering the prospect of a next-
generation regenerative solution for heart failure.
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Scientiﬁc advances profoundly impact evidence-based systems
of cardiovascular care [1]. In acute myocardial infarction,
coronary reperfusion along with adjuvant pharmacotherapy
has helped to ensure a Z96% in-hospital survival offering a
contemporary exemplar of improved outcomes [2]. Despite
reduced early mortality, 12% of patients die within 6 months
post-infarction and 25% of infarction survivors progressively
develop organ failure [3]. Hence, the emerging heart failure
epidemic is regarded as a paradox of medical success (Fig. 1) [4].
Chronic heart failure affects up to 30 million people world-
wide and highlights the growing burden of degenerative
diseases at a global scale [5]. About 1–2% of adults in
developed countries suffer from heart failure, with1016/j.tcm.2016.01.003
he Authors. Published by Elsevier Inc. This is an o
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thor at: Mayo Clinic, Stabile 5, 200 First St SW, Roc
terzic.andre@mayo.edu (A. Terzic).prevalence rising toZ10% in persons 70 years of age or older.
Liable for 42 million yearly hospitalizations in the United
States and Europe, heart failure is a primary indication for
repeated in-hospital care across geographies [6]. Survival
does not exceed 1 in 3 patients at 5-year follow-up [7]. These
staggering trends underscore pressing unmet needs of a
vulnerable aging population in spite of a generalized decline
in cardiovascular mortality rates.
Coronary artery disease underpins two-thirds of all systolic
heart failure—the best-known form of disease associated
with reduced ejection fraction. In patients who overcome
acute ischemic insult, initial survival is offset by progressive
organ failure requiring therapy escalation. As focus of ther-
apy shifts from mortality to consequences of survival, the
quest for treatments that reduce myocardial injury/limitpen access article under the CC BY-NC-ND license
hester, MN 55905. Tel.: þ1 507 284 2747.
Fig. 1 – The chronic heart failure epidemic in the context of
advances in acute coronary care. The 50-year-long trends
highlighting the impact of acute revascularization on
myocardial infarction (MI) mortality (red line), and
concomitant increase in heart failure hospitalizations (blue
line). Data represented as incidence per 10,000 persons and
normalized to U.S. Census population ﬁgures. Vertical
markers: institution of coronary artery bypass grafting
(CABG), percutaneous transluminal coronary angioplasty
(PTCA), thrombolytics (streptokinase and tPA), bare metal
stent (BMS), and drug eluting stent (DES). Dashed line:
percutaneous coronary intervention (PCI).
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serve ventricular function is paramount [8].Disease reversal goals
Heart failure therapy entails syndrome relief, prevention of
hospital admission, and mortality reduction [9]. To impact
quality of life and survival, disease management relies
largely on optimal titration of pharmacotherapy (i.e., beta
blockers, angiotensin-converting-enzyme inhibitors, aldos-
terone antagonists, and neprilysin inhibition), and use
of cardiac resynchronization as appropriate. Infarct size,
however, remains the main determinant of adverse post-
infarction aftermath, including a particularly poor clinical
outcome in worsening heart failure [10]. Current
approaches fail to address the fundamental issue of myo-
cyte loss that underlies incipient cardiomyopathy. In end-
stage disease, mechanical circulatory support, and organ
transplantation are extraordinary life-extending measures
limited by cost and access. To enhance standard of care,
innovative treatments aim to fundamentally alter the
course of disease, and avert end-stage deterioration and
need for transplantation [11].The U.S. Department of Health and Human Services per-
spective, “2020: A New Vision,” singles out regenerative
medicine at the core of health care innovation [12]. Exempli-
ﬁed by curative therapies offered in transfusion medicine and
in deﬁned hematological malignancies, regenerative technol-
ogies incorporate transplant of healthy tissues, induction of a
healing response in diseased tissues, and/or implement
tissue engineering to manufacture new tissue [13,14]. Regen-
erative innovations are introduced across medical and surgi-
cal specialties aiming at normative organ restitution
integrated in whole-person care. With the prospect of func-
tional and structural repair, regenerative solutions strive to
achieve disease reversal goals reducing medical and societal
imperatives of life-long disease management [15].Regenerative equation
The notion of the heart as an organ permissive of regeneration
is central in the rollout of regenerative paradigms applied to
cardiovascular medicine. Traditionally referred as a post-
mitotic, terminally differentiated organ, newer evidence sup-
ports a dynamic view of the human heart. Cell death versus
renewal incorporates vital components governing cardiac
homeostasis, aging, and disease [16]. During a person's life,
revitalizing mechanisms—particularly operational at a
younger age—contribute to ongoing renewal of the heart mass,
securing physiological tissue safeguard [17]. Regenerative
reserve reﬂects the ability to maintain homeostasis through
self-reparative mechanisms [18]. In disease, this innate pro-
pensity becomes inadequate to cope with cardiomyocyte loss
and ultimately fails to restore organ performance. In partic-
ular, with aging, the rejuvenative reserve is compromised as
decline in tissue health is compounded with accrual of
senescent cells [19]. Clearance of senescent cell pools improves
tissue function, yet falls short at restoring pre-aging status
[20]. In a permissive myocardial environment, regenerative
therapy is thus conceived as a boost to the innate repair
capacity aiming to restore regenerative ﬁtness.
Within a diverse and evolving regenerative toolkit that
includes standalone or combination techniques relaying on
cells/tissues/biomaterials, and/or molecules, stem cells and
derivatives are the most commonly tested active ingredient
[21–23]. Use of stem cells to buttress the regenerative for-
titude of ailing hearts leverages a presumed capacity to
recreate tissue and/or promote repair, and represents 25%
of all clinical development efforts in cell-based therapies [24].
Stem cells, envisioned to fulﬁll a building-block role to rebuild
compromised heart muscle, are increasingly thought to
actually stimulate a multifaceted regenerative response,
leading to an overhaul of the disease substrate within the
host myocardium. Indeed, a science that was initially highly
cell centric has undergone a fundamental re-examination,
moving away from the premise of a direct exogenous stem
cell-mediated regeneration toward the currently prevailing
hypothesis that therapeutic activity reﬂects primarily an
indirect, paracrine effect of delivered cells interacting with
the diseased myocardium to trigger an endogenous regener-
ative cascade. Multimodal repair mechanisms, implicating
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proposed in this regard [25].
Post-infarction, cell-based interventions aim at regenera-
tive prophylaxis of fragile injured hearts, that is, to limit early
damage by altering the myocardial response to injury, avert-
ing adverse remodeling, and avoiding or delaying organ
failure [26]. Beyond acute/subacute cardioprotection, in
advanced heart failure associated with protracted systolic
decompensation, the goal becomes cardiorestorative aimed
at reversal of contractile dysfunction, structural restoration,
and scar reduction [27]. Proposed strategies are supported by
wide-ranging pre-clinical proof-of-concept studies that serve
as a launch pad for testing in humans [28].
As a result, over the last decade, translation of stem cell
technology in clinical trials has been increasingly realized.
Across the cardiovascular disease spectrum, numerous phase I
and a growing number of phase II clinical trials have been
completed, testing various cell types and delivery protocols.
Accumulating data from early phase clinical experience docu-
ments safety and feasibility of delivering autologous or allo-
geneic therapies in a range of cardiovascular conditions, and
importantly provides a foundation to deﬁne parameters of
clinical efﬁcacy that justify further investigation in larger
clinical trials [29]. Clinical progress in developing convincing
and successful therapies, although steady, has been modest in
part attributed to rather small, underpowered trials using
surrogate end points and open-label treatment approaches
carrying the risk of bias [30]. A recent meta-analysis focused
on heart failure reﬂects on the state-of-the-art [31]. This
comprehensive study analyzed systematically 31 clinical trials
including over 1500 total participants (882 cell-treated and 639
control patients). Collectively, these trials encompass an
assortment of tested cell products ranging from bone
marrow-derived mononuclear cells, including granulocyte-
colony stimulating factor (G-CSF) mobilized sub-populations,
and bone marrow-derived mesenchymal stem cells to cardiac
stem cells, skeletal myoblast, and adipose tissue-derived cells
[31]. Supporting the safety record of cell-based therapies, this
meta-analysis underscores overall safety with minimal major
intervention-related adverse effects and no increase in the
incidence of arrhythmias [31]. Moreover, reduction in mortality
and re-hospitalization caused by worsening heart failure
during long-term follow up, along with moderate improve-
ment of left ventricular ejection fraction and improved heart
failure symptoms including exercise capacity were docu-
mented. However, performance/selection bias was deemed
considerable as only half of the analyzed trials reported
blinding of participants/clinicians, and roughly, half failed to
report methods of allocation concealment [31]. In fact, when
only double-blind studies were selected, the meta-analysis did
not reveal statistical difference between cell-treated versus
control groups [30,31]. Thus, encouraging feasibility and safety
proﬁles observed repeatedly in clinical testing have yet to
materialize into broadly validated clinical beneﬁt, dictating the
need for vigilant assessment of cell therapy practices [32]. In
this regard, it should be noted that the presumed biological
activity of a cellular product might greatly differ depending on
the cell source, cell preparation, and/or cell administration.
Moreover, among a number of variables, the state of the target
cardiac micro-environment dictates the efﬁcacy of mechanismscontributing to ultimate functional regeneration [30]. New
emphasis is thus placed on establishing quality control
procedures through development of standard operating prac-
tices for the harvesting, isolation, and expansion of cell
populations. Insights into the composition of stem cell
sources have, for example, paved the way toward approaches
that would eliminate non-regenerative cells to expand cell
populations that display multipotent traits possibly predict-
ing regenerative potency before intervention [32].Problem statement
Regenerative science must achieve “validity” (potential effec-
tiveness) and “utility” (likelihood of improved outcome) in
clinical settings to extend current care models, and provide a
value-added beneﬁt for patients and society at large [33]. Build-
out of regenerative service lines is predicated on effective
clinical-grade biotherapies suitable for scale-up and stand-
ardized production and application. A viable supply chain
requires quality-controlled manufacturing and delivery of
products that fulﬁll patient speciﬁcations [33]. At present, an
essential point of vulnerability that constrains translational
readiness and practice adoption is the inherent idiosyncrasy
and aleatory bioactivity of stem cell populations (Fig. 2) [34].
Patient modiﬁers—such as age, sex, morbidities, and con-
comitant therapies—impact regenerative ﬁtness. Cell per-
formance is also subject to inﬂuences during procurement,
production, and/or delivery [35]. In fact, not all individuals
harbor stem cells with a uniform reparative capacity. System-
atic analysis of national trial experience reveals that, in
patient cohorts, the incidence of reparative stem cells with
a clinically measurable cardio-regenerative aptitude is quite
rare—in the order of 5% [36]. The inconsistency in stem cell
effectiveness mandates means that would ensure consistent
efﬁcacy of treatment, including quantitative surrogates to
reliably predict the intended biological activity [37].Informing biotherapy evolution
Clinical trial experience provides an irreplaceable avenue to
inform the evolution of cardio-regenerative stem cell thera-
pies [30]. “First-generation” therapies are typically comprised
of mixed cell populations that generated largely mixed
results [38,39]. Heterogeneous clinical outcomes offer, how-
ever, a unique opportunity to delineate molecular under-
pinnings of true responders from non-responders (Fig. 2).
Surface markers alone may provide insufﬁcient resolution to
forecast cellular repair aptitude. Rather, regenerative from
non-regenerative cytotypes are segregated based on distinc-
tive molecular pathways that are starting to be elucidated
through high-throughput clinomics approaches leveraging
clinical trial specimens cross-referenced with individual
patient outcomes [36,40]. Non-regenerative cells remain con-
ﬁned to a state of perpetual stemness [39]. In contrast, rare
regenerative counterparts are milieu responsive, plastic, with
a deﬁnitive inclination for differentiation—traits of regener-
ative proﬁciency [40,41].
Fig. 2 – Heterogenous regenerative proﬁciency. Left column: harvest of unselected stem cell populations, which when
delivered as a singular intervention produce mixed results. Middle column: only 5% of patients with heart failure harbor stem
cells associated with clinically demonstrable beneﬁt. Right column: reparative cell populations are distinguished from non-
reparative counterparts by a distinct molecular signature reﬂecting functional plasticity.
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ensure that therapeutic stem cells will reliably function in the
target organ [42]. This requirement can, in principle, be
achieved through multiple strategies, including habituation
of the myocardial environment to improve on stem cell
homing upon delivery [43], anatomic matching of cell source
with target organ relying on resident stem cell pools [44], or
combined cell therapy [e.g., mesenchymal stem cells along
with c-kit(þ) cells] for synergistic effects that leverage coop-
erative cell-to-cell communication according to organ needs
[45,46]. We here zoom in on an alternative prototype platform
—cardiopoiesis—developed to mitigate variability inherent to
cell products/patients and integrate a quality system that
certiﬁes regenerative proﬁciency of a biotherapy candidate.Cardiopoiesis fundamentals
Cardiopoiesis imposes a lineage-specifying program on stem
cells to reinvigorate function and promote cardioreparative
proclivity [40,41]. Cardiopoiesis guides stem cells to (re)activate
cellular plasticity, (re)engage into cardiovasculogenesis, and (re)
set an active aptitude for repair (Fig. 3). This conditioning
paradigm draws from embryonic signals that instruct pre-
cardiac mesoderm to commit into the cardiomyogenic fate
[47]. Cues germane to the ventral endoderm of a developing
embryo guide, the anterolateral mesoderm ensuring deﬁnitive
cardiac program engagement, and avoidance of alternative
fates or uncontrolled growth [48]. Narrow windows deﬁning
developmental stages dictate the delicate nature in which
cardiogenic cues need to be introduced to promote cardio-
genesis from an embryonic stem cell source, exempliﬁed in thecomplex dynamics of TGF-β superfamily signaling guiding
pluripotent stem cell fate choices [49,50]. A systems biology-
resolved cardiopoietic atlas revealed an integrated and tract-
able molecular network fundamental to lineage speciﬁcation
[51]. Using endodermal cell lines, the cardio-inductive aptitudes
of secreted cytokines and growth factors have been screened—
a process facilitated by the stress cytokine TNF-α that spikes
the cardiogenicity of the endodermal secretome [52]. Resolving
the unprimed endodermal secretome vis-a-vis that of the TNF-
α-enhanced endoderm enabled dissection of molecules that
coax stem cells into cardiac fate. Through this approach, a
cocktail of critical factors was formulated to recapitulate
required cardiogenic cues [53]. An initial version included
TGF-β1, BMP-2/4, FGF-2/4, IL-6, IGF-1/2, VEGF-A, EGF, and
Activin-A, where staged factor combinations created a syner-
gistic environment, which promotes the upregulation and
nuclear translocation of cardiac transcription factors, including
homeobox transcription factor Nxk2.5, zinc ﬁnger-containing
transcription factor GATA-4, and myocyte enhancer factor
MEF2C. Directed differentiation allows lineage mapping of
embryonic stem cells, as they transition from pluripotency to
a cardiogenically oriented multipotent fate. The distinguishing
feature of the derived intermediate cell phenotype, termed
cardiopoietic stem cell, is the capacity to uniquely yield
cardiovascular lineages [40,48,53]. Cardiopoietic stem cells are
deﬁned by nuclear translocation of cardiac transcription factors
(low in unguided stem cells) and absence of sarcomerogenesis
(typical of mature cardiomyocytes). In density gradients,
sarcomere-poor cardiopoietic stem cells are readily separated
from cardiomyocytes. A low-density cardiopoietic stem cell
culture (1500 cells/cm2) placed in the cardiogenic cocktail yields
a 10%, 30%, and 65% population of cardiomyocytes by 3, 6, and
Fig. 3 – Targeted (re)activation of latent plasticity in adult stem cells augments the repair quotient. Left: cardiopoiesis, via
cardiogenic cues, guides patient-derived stem cells into a state of active cellular plasticity and cardiovasculogenesis to
augment repair aptitude. Right: increase of cardiac repair propensity in stem cells following cardiopoietic guidance.
T R E N D S I N C A R D I O V A S C U L A R M E D I C I N E 2 6 ( 2 0 1 6 ) 3 9 5 – 4 0 4 39910 days, respectively [41]. In this way, cardiopoiesis enables
targeted generation of lineage-speciﬁed stem cells [54].Translating cardiopoiesis
Principles discovered in embryonic platforms are translatable
into clinically apt practices (Fig. 4). A cardiogenic cocktail-rich
milieu can guide patient-derived adult stem cells to acquire a
repair potential associated with cardiac transcription factor
expression [40,54]. Adult stem cells suffering from seques-
tered plasticity are resuscitated by priming with recombinant
factors TGF-β, BMP-4, Activin-A, IGF-1, IL-6, FGF-2, thrombin,
and retinoic acid that mimic signals and pathways activated
in natural cardiogenesis. Of note, however, the biological
outcome of cardiopoiesis applied to an adult stem cell
population should be distinguished from that of pluripotent
counterparts, as it intends to achieve a regenerative paracrine
function in the heart rather than to recapitulate embryonicFig. 4 – Cardiopoiesis platform: translating discovery into applicat
guided translation and scale-up of lineage-speciﬁed stem cells mcardiomyogenesis [40,48]. The ﬁrst clinically tested example
of such an approach is lineage speciﬁcation through con-
ditioning of bone marrow-derived mesenchymal stem cells
from patients with ischemic heart failure to yield the car-
diopoietic stem cell phenotype [40,41,54]. In mesenchymal
stem cells, simultaneous activation with TGF-β, BMP-4, and
Activin-A along with retinoic acid induces cytosolic expres-
sion of cardiac transcription factors, while IGF-1 and IL-6
prompt their nuclear translocation (Fig. 3). Such co-
stimulation typically results in cell cycle arrest of primed
mesenchymal stem cells precluding cell propagation to
achieve a therapeutic dose needed in man. To this end,
FGF-2 and thrombin are utilized to maintain cell cycle activity
(Fig. 3). Compared to lineage-unspeciﬁed mesenchymal stem
cells, delivery of derived cardiopoietic stem cells into an
infarcted failing heart demonstrates improved therapeutic
impact on follow-up [40]. Limited cell grafting detectable
long-term contrasts the maintained functional beneﬁt, impli-
cating indirect mode of action that harnesses endogenousion. Deconvoluted molecular events underlying cardiogenesis
anufactured for clinical application.
T R E N D S I N C A R D I O V A S C U L A R M E D I C I N E 2 6 ( 2 0 1 6 ) 3 9 5 – 4 0 4400repair pathways [40,55]. Although rare, head-to-head studies
of different transplanted cell types indicate functional supe-
riority of those whose phenotype is close to that of the target
tissue, that is, cells committed toward a cardiac lineage [55].
Pre-emptive cardiopoietic conditioning could thus serve to
expand the number of patients potentially beneﬁting from
stem cell therapy by converting the naïve, typically non-
reparative, source into a reparative cytotype [56,57].
A biomarker-based measure to anticipate therapeutic efﬁ-
cacy of adult stem cells prior to transplantation was in
accordance developed. The “cardiopoietic index” employs a
gene-expression proﬁling as a means to assess the regener-
ative quotient of patient-derived cells [58]. The index reﬂects
an integrated readout, based on the messenger RNA expres-
sion of cardiogenic transcription factors Nkx2.5, MEF2c, Gata-
4, Gata-6, Fog-1, MESP1, and Tbx5. Application of this quality
control standard allows pre-assessment of repair potential at
time of cell harvest predicting individuals harboring stem
cells with an innate capacity for repair versus those with
non-reparative cells, where switch-on of pro-regenerative
signaling is needed. The cardiopoietic index is a gauge of
functional beneﬁt (measured as ejection fraction change)
with a reported sensitivity and speciﬁcity of 91% and 95%,
respectively [58].
Ensuring a robust cardiopoietic yield would be valuable,
particularly in conditioning stem cells derived from elderly
patients. An example of strategy currently investigated to
maintain youthful status is the titration of nucleostemin
functionality. This nucleolar stress sensor works by stabiliz-
ing stemness gene programs through pro-survival pathways
with nucleostemin overexpression reducing senescent traits
in support of tissue youth [59], thus providing a means to
adjust regenerative potential on a need-be basis [19].Cardiopoiesis in the clinic
To achieve clinical application of a stem cell-based technol-
ogy, scalable standard operating procedures are utilized.
Proper dose ramp up, in tandem with suitable bio-distribu-
tion, are some of the basic requirements for safety and
efﬁcacy to reﬂect pre-clinical data [60,61]. The stringency of
good manufacturing practice is employed to ensure clinical-
grade manufacturing of derived cellular products that must
meet purity, potency, and sterility metrics. ManufacturedFig. 5 – Multitier release criteria offer a quality control system to
infrastructure conforming to Good Manufacturing Practice stand
lineage-speciﬁed cellular product. A logistics-supervised distribcardiopoietic stem cells require a multitier release schedule,
which ﬁrst establishes homogeneity of the mesenchymal
stem cell source through cell surface marker proﬁling. This
is followed by establishment of purity through gene proﬁling
to ensure that the therapeutic formulation is devoid of
divergent, non-cardio-regenerative contaminants. Finally,
documented nuclear translocation of a select cardiopoietic
index marker ensures potency (Fig. 5).
The impact of cardiopoietic stem cells on patients with
established ischemic heart failure was investigated in the C-
CURE trial (Cardiopoietic stem Cell therapy in heart failURE;
ClinicalTrials.gov Identiﬁer: NCT00810238; Fig. 6). This phase II,
randomized, and prospective multicenter study evaluated the
feasibility and safety of the cardiopoiesis-based technology in
patients with chronic heart failure of ischemic origin while
monitoring for efﬁcacy signals [62]. Cardiopoietic stem cells
were implanted, using direct endomyocardial delivery [63], on
average 1500 days after myocardial infarction. Patients were
randomized to receive cardiopoietic stem cells plus standard of
care, in the therapy arm, versus standard of care alone in the
control arm. Following the cardiopoiesis algorithm, the C-CURE
trial pre-emptively treated patient-derived mesenchymal stem
cells with the cardiogenic cocktail to achieve guidance toward a
lineage speciﬁed state [62]. There was no evidence of cardiac or
systemic toxicity induced by cardiopoietic cell therapy. In
addition, left ventricular ejection fraction was improved in
the cardiopoietic stem cells therapy arm compared to standard
of care alone, and associated with reduction in left ventricular
end-systolic volume. A favorable impact on global parameters
such as 6-min walk distance was also noted, along with beneﬁt
in a composite clinical score encompassing cardiac as well as
general wellness parameters [62].
These results serve to support further investigation [64],
including a multinational phase III clinical trial, named
CHART-1 (Congestive Heart Failure Cardiopoietic Regenera-
tive Therapy), currently in the follow up phase [65]. Patients
with chronic heart failure secondary to ischemic heart dis-
ease, reduced left ventricular ejection fraction (o35%),
and at high risk for recurrent heart failure-related events,
were randomized in CHART-1 to receive 600  106 bone
marrow derived and lineage-directed autologous cardio-
poietic stem cells (administered via a retention-enhanced
intra-myocardial injection catheter [66]) or a sham procedure
(ClinicalTrials.gov Identiﬁer: NCT01768702). The primary efﬁ-
cacy end point of the CHART-1 study is a hierarchicalensure optimal regenerative proﬁciency. A quality system
ards is needed for procurement, manufacture, and release of
ution insures delivery of stable product for clinical use.
Fig. 6 – Clinical implementation of the lineage-guidance paradigm in cell therapy. The C-CURE (Cardiopoietic stem Cell therapy
in heart failURE) trial was conducted in patients with ischemic heart failure. Bone marrow was harvested (step 1) and isolated
mesenchymal stem cells (step 2) lineage speciﬁed by cardiogenic cocktail priming (step 3). Cardiopoietic stem cells meeting
release criteria were delivered by endomyocardial injections (step 4). On follow-up, signs of efﬁcacy were documented (step 5).
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Living with Heart Failure Questionnaire score, 6-min walk
test, left ventricular end-systolic volume, and left ventricular
ejection fraction at 9 months [65]. The secondary efﬁcacy end
point is the time to cardiovascular death or worsening heart
failure at 12 months. Safety end points include mortality,Fig. 7 – Clinomics-based optimization algorithm informs next-g
documented in cardiovascular clinical trials underscore a limita
clinomics strategies provide the opportunity to delineate the mo
informing next-generation strategies. Use of a priming platform
phenotype exempliﬁes such an optimizing approach aimed to ereadmissions, aborted sudden deaths, and serious adverse
events at 12 and 24 months. The CHART-1 clinical trial is
powered to examine the therapeutic impact of lineage-
directed stem cells as a strategy to achieve cardiac regener-
ation in heart failure populations [65]. On completion, the
CHART-1 trial is designed to offer a deﬁnitive evaluation ofeneration regenerative biotherapies. Mixed outcomes
tion of ﬁrst generation stem cell regimens. High-throughput
lecular underpinnings of responders versus non-responders
to guide patient-derived stem cells into a pro-reparative
nsure beneﬁt in heart failure patient populations.
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treatment of chronic ischemic heart failure [67].Outlook
Standard of care in heart failure aims to reverse disease
course and reduce adverse outcomes. Countering post-
infarction parenchymal loss, patients display different tra-
jectories of disease progression [68] compounded by age-
mediated cardiac vulnerability [69]. Introduction of regener-
ative regimens in management algorithms is conceived to
complement, and potentially transform the available arma-
mentarium. Early experience in clinical cardiac regeneration
supports the compatibility of stem cell-based therapies as
adjuvants to established practice [70]. However, lack of
therapeutic consistency inherent to patient-derived stem cell
populations remains a central hurdle limiting adoption.
The regenerative capacity of stem cells is inﬂuenced by
multiple factors dictating the proclivity for tissue health
restoration [71]. Importantly, therapeutic inconsistency in
clinical trials provides a kaleidoscope of biological systems
activity across the range of observed regenerative beneﬁt
(Fig. 7). Leveraging clinomics-based interrogation, biological
deconvolution informs the development of new high-ﬁdelity
protocols endowed with a resolution needed to ensure cell
repair potency prior to application. A prototype approach is
cardiopoiesis that inculcates lineage speciﬁcation, condition-
ing stem cells with recombinant cardiogenic cues to endow
therapeutic proﬁciency in heart failure. Accordingly, a mul-
titier quality system to verify homogeneity, purity, and
potency-associated markers for release of manufactured
clinical-grade cardiopoietic stem cells has been rolled-out.
The cardiopoietic stem cell phenotype is currently tested in
advanced clinical trials for chronic heart failure exemplifying
a next-generation biotherapy optimized for regenerative
proﬁciency.
Beyond validity, the utility of newest regenerative options
will inform adoption reﬂecting real-world experience with
emerging treatments poised to address unmet needs of
broader populations [72,73]. Modern clinical development
algorithms of candidate technology incorporate multidiscipli-
nary assessment by health care providers, developers, regu-
lators, and payers [74] and seek active patient engagement
[75]. This evolving landscape heralds an evolution in the
medical product development and authorization lifecycle of
novel therapies, from a paradigm focused on the therapeutics
to a holistic evaluation that integrates the patient within a
health care regimen.Acknowledgments
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